An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...

The winners will receive a cash contribution of €25,000 for the first prize winner, €15,000 for the second prize winner, ...

India’s rental landscape is fast evolving, with Tier 2 and 3 cities emerging as hotspots for growing housing demand. As ...

Kolkata: A man, who repeatedly took a second-hand sedan car on test drives, allegedly stole the vehicle from a used-car ...

A car drove into a crowd of people in the western German city of Mannheim on Monday, killing at least one person, injuring ...

A man with a chainsaw suffers a moment right out of a cartoon on top of a frozen lake in Derezivka, Ukraine on February 16, cutting a hole in the ice all the way around himself before falling into the ...

However, it is possible to sell the note for a higher price through certain avenues, such as websites and apps like eBay and OLX. This special Rs 50 note must feature the number 786 inscribed on it, ...

OliX Pharmaceuticals, a listed company on the KOSDAQ, has been designated as an investment warning stock due to a sharp rise in its stock price, and if the stock price rises further on the 18th ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...

South Korea-based OliX Pharmaceuticals, Inc., a developer of RNAi therapeutics, entered a global licensing agreement with Eli Lilly and Co. focused on the development and commercialization of OliX’s ...

Meanwhile, Eli Lilly signed a global licensing deal for a MASH asset with South Korea’s OliX Pharmaceuticals. Speaking of controversy, Regeneron is suing its Dupixent partner Sanofi, claiming the ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...